TiumBio
A drug developer working on treatments for cancer based in South Korean.
| KRW | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | (6 %) | (95 %) | 15896 % | (46 %) | 39 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (646 %) | (1171 %) | (53953 %) | (243 %) | (247 %) | (13 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (637 %) | (1155 %) | (55504 %) | (327 %) | (366 %) | (304 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | 937 % | 45266 % | 233 % | 365 % | 140 % |
Source: Company filings or news article
Related Content
TiumBio is a globally recognized research and development company focused on creating innovative treatments for rare and incurable diseases. The company operates in the biopharmaceutical sector, targeting unmet medical needs through the development of new drugs. TiumBio serves a diverse range of clients, including healthcare providers, hospitals, and patients suffering from rare conditions. The company’s business model revolves around extensive research and clinical trials to bring novel therapies to market. Revenue is generated through the commercialization of these drugs, partnerships with other pharmaceutical companies, and licensing agreements. TiumBio's commitment to innovation is evident in its pipeline of promising treatments, such as merigolix for endometriosis and TU2218, a dual inhibitor aimed at enhancing the efficacy of immuno-oncology drugs. The company’s core values emphasize true innovation, excellence, and continuous improvement, driving its mission to improve human health and happiness.
Keywords: biopharmaceutical, rare diseases, innovative treatments, clinical trials, healthcare providers, novel therapies, commercialization, partnerships, licensing, immuno-oncology.
